Adnkronos Rome, October 10 (Adnkronos Salute) – The National Congress of the Italian Association of Hemophilia Centers (AICE) is just around the corner, scheduled for October 16-18 in Rome. This event represents a key event for the Italian scientific community engaged in the treatment and research of congenital bleeding disorders. "This congress represents an opportunity for professionals to exchange clinical experiences and promote increasingly consistent and personalized standards of care," says Rita Carlotta Santoro, president of the congress.
This year's edition, as explained in a press release, comes at a time of significant evolution for the Italian hematology community. A growing number of centers have embarked on the path to gene therapy, a frontier that is redefining the treatment landscape for many patients. At the same time, new molecules are appearing on the market, offering increasingly specific and targeted tools to address the diverse facets of hemophilia and other bleeding disorders. The program reflects this dynamic trend and will offer sessions dedicated to both innovative therapeutic strategies and their practical implications: from patient selection to management of side effects, to optimizing treatment pathways. Ample space will also be dedicated to AICE working groups, a crucial opportunity for discussion and the development of new ideas and projects, leveraging the contributions of young professionals and all those working in the centers. The scientific sessions and meetings with supporting members will offer timely updates on the topics of greatest clinical and therapeutic interest, fostering open debates and shared reflections that will strengthen dialogue and collaboration among all participants. The congress represents an opportunity for growth and unity for the national scientific community, committed to improving the quality of care and lives of people with haemophilia.